Breath test for lung cancer to be trialled this year
17 February, 2015UK-based company Owlstone Nanotech has devised the LuCID (Lung Cancer Indicator Detection) project - an attempt to non-invasively diagnose lung cancer by measuring volatile organic compounds (VOCs) in patients' breath.
Epigenetic patterns differentiate triple-negative breast cancers
04 February, 2015Australian researchers have identified a new method that could help tell the difference between highly aggressive and more benign forms of triple-negative breast cancer (TNBC).
Qiagen QuantiFERON Monitor for tracking immune function in solid organ transplant patients
29 January, 2015Qiagen has announced the QuantiFERON Monitor (QFM), a novel diagnostic for monitoring immune function. It is available in non-European markets for research use as an accurate marker of immune function in studies of immunosuppressive conditions, immune modulating therapies and recovery following transplantation.
Qiagen QuantiFERON Monitor for tracking immune function in solid organ transplant patients
29 January, 2015Qiagen has announced the QuantiFERON Monitor (QFM), a novel diagnostic for monitoring immune function. It is available in non-European markets for research use as an accurate marker of immune function in studies of immunosuppressive conditions, immune modulating therapies and recovery following transplantation.
Why do young people have strokes?
28 January, 2015Researchers from The Centenary Institute, Sydney, have announced a breakthrough in understanding the cause of stroke in young people. The leader of the research, Dr Xiangjian Zheng, said the stroke in question affects around five in every 1000 people, many of whom are diagnosed in their 30s and 40s.
Regulatory registration of Qiagen lung cancer companion diagnostic
14 January, 2015Qiagen has announced the CE-IVD marking of its liquid biopsy-based companion diagnostic that analyses circulating nucleic acids obtained from blood samples to assess a genomic mutation in patients with non-small cell lung cancer (NSCLC).
Identification of a pre-cancerous state in the blood
10 December, 2014US researchers have uncovered a 'pre-malignant' state in the blood that significantly increases the likelihood that an individual will develop blood cancers such as leukaemia, lymphoma or myelodysplastic syndrome.
Low-cost technique to detect rotavirus
08 October, 2014Researchers at the Universidad Politécnica de Madrid (UPM) have found a new, low-cost way to enhance detection capacity of small concentrations of rotavirus - a sphere-shaped virus up to 75 nm in diameter that has the appearance of a wheel, seen from an electron microscope.
The molecular details of coeliac disease
01 May, 2014Australian, US and Dutch researchers have determined the molecular details of the interaction between the immune system and gluten that triggers coeliac disease.
Starpharma tech applied to AstraZeneca cancer drug
08 April, 2014Melbourne-based biotech company Starpharma has signed an expanded agreement with biopharma company AstraZeneca in the field of cancer medicine. The new agreement will see the application of Starpharma's dendrimer technology to a cancer drug from AstraZeneca's pipeline.
Diagnostic device meets malaria field evaluation objective
25 March, 2014Fio Corporation's Deki Reader - a mobile in vitro diagnostic device - has demonstrated consistent interpretation of rapid diagnostic tests (RDTs) for multiple malaria strains in a field evaluation.
Turning the spotlight on breast cancer cells
20 March, 2014Scientists are using the latest in nano-flare technology to detect breast cancer cells early on.
Drug testing with synthetic livers
19 March, 2014Scientists from clinical intelligence company Empiriko have developed chemosynthetic liver technology which could enable the testing of drug candidates without using animals.
Biomarkers reveal short-term risk of death
05 March, 2014Researchers from Finland and Estonia have discovered novel biological markers that indicate an individual's risk of dying from any disease in the near future.
Successful phase 2 results in Huntington disease trial
24 February, 2014Prana Biotechnology has announced the results of its phase 2 clinical trial investigating the drug PBT2 as a treatment for Huntington disease.
